Table 2.

Upcoming and planned daratumumab trials.

Study/phase	Population	Treatment
ALCYCONE (MMY3007) phase III	NDMM, not eligible for ASCT	DARA + VMP versus VMP
CASSIOPEIA (MMY3006) phase III	NDMM, eligible for ASCT	DARA + VTD versus VTD
MAIA (MMY3008) phase III	NDMM, not eligible for ASCT	DARA + LEN/DEX versus LEN/DEX
SQ daratumumab	RRMM	DARA + recombinant human hyaluronidase
CENTAURUS (SMM2001), phase II	High-Risk smoldering MM	DARA monotherapy

ASCT, autologous stem cell transplantation; DARA, daratumumab; DEX, dexamethasone; LEN, lenalidomide; MM, multiple myeloma; NDMM, newly diagnosed multiple myeloma; RRMM, relapsed/refractory multiple myeloma; SQ, subcutaneous; VMP, bortezomib, melphalan, prednisone; VTD, bortezomib, thalidomide, dexamethasone.